Academic Journal

A pediatric regimen for adolescents and young adults with Philadelphia chromosome-negative acute lymphoblastic leukemia : Results of the ALLRE08 PETHEMA trial

التفاصيل البيبلوغرافية
العنوان: A pediatric regimen for adolescents and young adults with Philadelphia chromosome-negative acute lymphoblastic leukemia : Results of the ALLRE08 PETHEMA trial
المؤلفون: Ribera, Jose-Maria, Morgades, Mireia, Montesinos, Pau, Tormo, Mar, Martínez-Carballeira, Daniel, González-Campos, José, Gil, Cristina, Barba, Pere, García-Boyero, Raimundo, Coll, Rosa, Pedreño, María, Ribera Salas, Jordi, Mercadal, Santiago, Vives Polo, Susana, Novo, Andrés, Genescà , Eulà lia, Hernández Rivas, Jesús María, Bergua Burgues, Juan Miguel, Amigo, María-Luz, Vall-Llovera, Ferran, Martínez-Sánchez, Pilar, Calbacho, Maria, Garcia Cadenas, Irene, Garcia-Guiñón, Antoni, Sánchez-Sánchez, María-José, Cervera, Marta, Feliu Frasnedo, Evarist, Orfao, Alberto, Universitat Autònoma de Barcelona
سنة النشر: 2020
المجموعة: Universitat Autònoma de Barcelona: Dipòsit Digital de Documents de la UAB
مصطلحات موضوعية: Acute lymphoblastic leukemia, Adolescents and young adults, Pediatric treatment
الوصف: Altres ajuts: Supported in part by grants from Fundació La Caixa and CIBERONC (JMHR and AO). ; Pediatric-based or -inspired trials have improved the prognosis of adolescents and young adults (AYA) with Philadelphia chromosome-negative (Ph-neg) acute lymphoblastic leukemia (ALL). This study reports the results of treatment of the ALLRE08 trial, a full pediatric trial for AYA aged 15-30 years with standard-risk (SR) ALL. From 2008 to 2018, 89 patients (38 adolescents [15-18 years] and 51 young adults [YA, 19-30 years], median age: 20 [15-29] years) were enrolled in the ALLRE08 trial. The complete response (CR) was 95%. Twenty-two patients were transferred to a high-risk (HR) protocol because of poor marrow response on day 14 (n = 20) or high-level of end-induction minimal residual response (MRD ≥ 0.25%, n = 2). Cumulative incidence of relapse (CIR) at 5 years was 35% (95%CI: 23%-47%), with significant differences between adolescents and YA: 13% (4%-28%) vs 52% (34%-67%), P = .012. No treatment-related mortality was observed in 66/66 patients following the ALLRE08 trial vs 3/23 patients moved to a HR trial. The estimated 5-year overall survival (OS) was 74% (95%CI: 63%-85%), with significantly higher rates for adolescents vs YA: 87% (95%CI: 74%-100%) vs 63% (46%-80%), P = .021. Although CIR or OS were lower in patients who were transferred to a HR trial, the differences were not statistically significant (CIR: 34% [21%-47%] vs 37% [14%-61%]; OS: 78% [66%-90%] vs 61% [31%;91%]). A full pediatric trial is feasible and effective for AYA with Ph-neg, SR-ALL, with better results for adolescents than for YA. Outcome of patients with poor early response rescued with a HR trial was not significantly inferior. A full pediatric trial is feasible and effective for adolescent and young adults with acute lymphoblastic leukemia, with better results for adolescents than for young adults. The outcome of patients showing poor early response was not significantly inferior than that observed for good responders after being ...
نوع الوثيقة: article in journal/newspaper
وصف الملف: application/pdf
اللغة: English
تدمد: 20457634
Relation: Instituto de Salud Carlos III PI14-01971; Agència de Gestió d'Ajuts Universitaris i de Recerca SGR288; Cancer Medicine; Vol. 9 (february 2020), p. 2317-2329; https://ddd.uab.cat/record/226242; urn:10.1002/cam4.2814; urn:oai:ddd.uab.cat:226242; urn:pmid:32022463; urn:pmcid:PMC7131850; urn:pmc-uid:7131850; urn:articleid:20457634v9p2317; urn:oai:pubmedcentral.nih.gov:7131850; urn:oai:egreta.uab.cat:publications/2e029cb4-f383-4292-ad7a-82f2221bd160
الاتاحة: https://ddd.uab.cat/record/226242
Rights: open access ; Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original. ; https://creativecommons.org/licenses/by/4.0/
رقم الانضمام: edsbas.16F9A503
قاعدة البيانات: BASE